Skip to content

Desmopressin melt therapy in nocturnal polyuria patients: pharmacokinetic/dynamic study

Desmopressin melt therapy in nocturnal polyuria patients: pharmacokinetic/dynamic study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-004540-22-BE
Enrollment
Unknown
Registered
2011-09-14
Start date
2011-10-25
Completion date
Unknown
Last updated
2015-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nocturia and noctural polyuria MedDRA version: 14.0 Level: LLT Classification code 10064016 Term: Nocturnal polyuria System Organ Class: 10038359 - Renal and urinary disorders

Interventions

Trade Name: Minirin Melt 120 µg Product Name: Desmopressin Pharmaceutical Form: Oral lyophilisate INN or Proposed INN: DESMOPRESSIN ACETATE CAS Number: 62357-86-2 Concentration unit: µg microgram(s) C

Sponsors

Ghent University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Written informed consent prior to the performance of any study-related activity - Patients 18 years and older with an average of = 2 nocturnal voids per night Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10

Exclusion criteria

Exclusion criteria: - hypersensitivity/anaphylactic reaction on desmopressin or one of the other substances - pregnancy - genito-urinary tract pathology (infection, tumor,...) - urolithiasis - suspicion or evidence of cardiac failure - moderate to severe renal insufficiency (creatinin clearance < 50 ml/min) - psychogenic or habitual polydipsia - hyponatriemia or predisposition for hyponatriemia - diabetes insipidus - syndrome of inadequate ADH production

Design outcomes

Primary

MeasureTime frame
Main Objective: To determine the pharmacokinetic/dynamic (PK/PD) characteristics of desmopressin melt in nocturia patients ;Secondary Objective: To determine the reduction of the urine production;Primary end point(s): Blood levels of desmopressin;Timepoint(s) of evaluation of this end point: After 1,2,3,6 and 12 hours of intake of desmopressin melt

Secondary

MeasureTime frame
Secondary end point(s): Urine production;Timepoint(s) of evaluation of this end point: After 1,2,3,6 and 12 hours of intake of desmopressin melt

Countries

Belgium

Contacts

Public ContactTrial Bureau

Ghent University Hospital

Trialbureau@uzgent.be+3293320500

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026